Glucagon-like peptide 1 (GLP-1) receptor agonists have moved into the mainstream as pharmacologic adjuncts for weight loss, with proven safety and efficacy in patients with and without diabetes [9]. This evidence concerns the gene GLP1R and diabetes mellitus.